Skip to main content

Breast Cancer Research

Ausgabe 6/2012

Inhalt (26 Artikel)

Viewpoint

Chemosensitivity and p53; new tricks by an old dog

Per E Lønning, Stian Knappskog

Erratum

Erratum to: Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer

Jisun Kim, Wonshik Han, Hyeong-Gon Moon, Soo K Ahn, Hee-Chul Shin, Jee-Man You, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Hye R Koo, Jung M Chang, Nariya Cho, Woo K Moon, Dong-Young Noh

Editorial

S-nitrosylation of Ras in breast cancer

Harvey E Marshall, Matthew W Foster

Open Access Research article

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

Helena Linardou, Konstantine T Kalogeras, Ralf Kronenwett, George Kouvatseas, Ralph M Wirtz, Flora Zagouri, Helen Gogas, Christos Christodoulou, Angelos K Koutras, Epaminondas Samantas, Dimitrios Pectasides, Dimitrios Bafaloukos, George Fountzilas

Erratum

Erratum to: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer

Valerie Cortez, Monica Mann, Seshidhar Tekmal, Takayoshi Suzuki, Naoki Miyata, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Anil K Sood, Ratna K Vadlamudi

Open Access Research article

Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer

Sze-Yee Phuah, Lai-Meng Looi, Norhashimah Hassan, Anthony Rhodes, Sarah Dean, Nur Aishah Mohd Taib, Cheng-Har Yip, Soo-Hwang Teo

Open Access Research article

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX

Alan S Coates, Ewan KA Millar, Sandra A O'Toole, Timothy J Molloy, Giuseppe Viale, Aron Goldhirsch, Meredith M Regan, Richard D Gelber, Zhuoxin Sun, Monica Castiglione-Gertsch, Barry Gusterson, Elizabeth A Musgrove, Robert L Sutherland

Open Access Research article

Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance

Anne S Quante, Alice S Whittemore, Tom Shriver, Konstantin Strauch, Mary B Terry

Open Access Research article

The influence of mammogram acquisition on the mammographic density and breast cancer association in the mayo mammography health study cohort

Janet E Olson, Thomas A Sellers, Christopher G Scott, Beth A Schueler, Kathleen R Brandt, Daniel J Serie, Matthew R Jensen, Fang-Fang Wu, Marilyn J Morton, John J Heine, Fergus J Couch, V Shane Pankratz, Celine M Vachon

Open Access Research article

ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR

Christoforos Thomas, Gayani Rajapaksa, Fotis Nikolos, Ruixin Hao, Anne Katchy, Catherine W McCollum, Maria Bondesson, Phil Quinlan, Alastair Thompson, Savitri Krishnamurthy, Francisco J Esteva, Jan-Åke Gustafsson

Open Access Research article

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone

Anna A Mourskaia, Eitan Amir, Zhifeng Dong, Kerstin Tiedemann, Sean Cory, Atilla Omeroglu, Nicholas Bertos, Véronique Ouellet, Mark Clemons, George L Scheffer, Morag Park, Michael Hallett, Svetlana V Komarova, Peter M Siegel

Open Access Research article

A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications

Michael Marotta, Xiongfong Chen, Ayako Inoshita, Robert Stephens, G Thomas Budd, Joseph P Crowe, Joanne Lyons, Anna Kondratova, Raymond Tubbs, Hisashi Tanaka

Open Access Research article

Alcohol and breast cancer risk among Asian-American women in Los Angeles County

Anna H Wu, Cheryl Vigen, Pedram Razavi, Chiu-Chen Tseng, Frank Z Stancyzk

Open Access Research article

Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors

Amanda Cañas, Laura M López-Sánchez, Araceli Valverde-Estepa, Vanessa Hernández, Elena Fuentes, Juan R Muñoz-Castañeda, Chary López-Pedrera, Juan R De La Haba-Rodríguez, Enrique Aranda, Antonio Rodríguez-Ariza

Open Access Research article

Interplay between neural-cadherin and vascular endothelial-cadherin in breast cancer progression

Maryam Rezaei, Katrin Friedrich, Ben Wielockx, Aleksandar Kuzmanov, Antje Kettelhake, Myriam Labelle, Hans Schnittler, Gustavo Baretton, Georg Breier

Open Access Research article

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study

Kerstin Rhiem, Christoph Engel, Monika Graeser, Silke Zachariae, Karin Kast, Marion Kiechle, Nina Ditsch, Wolfgang Janni, Christoph Mundhenke, Michael Golatta, Dominic Varga, Sabine Preisler-Adams, Tilman Heinrich, Ulrich Bick, Dorothea Gadzicki, Susanne Briest, Alfons Meindl, Rita K Schmutzler

Open Access Research article

Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes

Colleen A Fordyce, Kelley T Patten, Tim B Fessenden, RosaAnna DeFilippis, E Shelley Hwang, Jianxin Zhao, Thea D Tlsty

Open Access Research article

Modelling the overdiagnosis of breast cancer due to mammography screening in womenaged 40 to 49 in the United Kingdom

Necdet B Gunsoy, Montserrat Garcia-Closas, Sue M Moss

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.